Immunovant (NASDAQ:IMVT) Stock Falls 6.9% – Should You Sell?

Posted by George Bondi on Oct 8th, 2026

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report)’s stock price fell 6.9% on Thursday. The stock traded as low as $30.00 and last traded at $29.8140. Approximately 398,114 shares were traded during trading, a decline of 74% from the average session volume of 1,507,574 shares. The stock had previously closed at $32.04.

Analyst Ratings Changes

A number of research firms have recently commented on IMVT. Citigroup reaffirmed a “positive” rating on shares of Immunovant in a research note on Thursday, September 24th. Sanford C. Bernstein upgraded shares of Immunovant to a “hold” rating in a research note on Wednesday, July 29th. HC Wainwright reaffirmed a “buy” rating on shares of Immunovant in a research report on Thursday, September 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunovant in a research note on Friday, October 2nd. Finally, JPMorgan Chase & Co. lifted their price target on shares of Immunovant from $47.00 to $50.00 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. Eight equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.00.

View Our Latest Stock Analysis on IMVT

Immunovant Trading Down 5.8%

The firm’s 50-day moving average price is $38.76 and its two-hundred day moving average price is $34.41. The stock has a market cap of $6.24 billion, a PE ratio of -10.70 and a beta of 0.84.

Immunovant (NASDAQ:IMVT – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.12). The company had revenue of $7.09 million for the quarter, compared to the consensus estimate of $7.09 million. During the same quarter last year, the firm posted ($0.71) earnings per share. On average, analysts anticipate that Immunovant, Inc. will post -2.96 earnings per share for the current year.

Insider Buying and Selling at Immunovant

In related news, Director Atul Pande sold 1,500 shares of the company’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $43.27, for a total transaction of $64,905.00. Following the completion of the sale, the director directly owned 116,731 shares in the company, valued at $5,050,950.37. This represents a 1.27% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Christopher Van Tuyl sold 2,846 shares of the company’s stock in a transaction on Wednesday, September 23rd. The stock was sold at an average price of $36.36, for a total value of $103,480.56. Following the sale, the insider owned 176,545 shares of the company’s stock, valued at $6,419,176.20. This trade represents a 1.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 7,852 shares of company stock valued at $287,975. 1.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Immunovant

Several institutional investors and hedge funds have recently added to or reduced their stakes in IMVT. Two Seas Capital LP boosted its holdings in shares of Immunovant by 46.5% in the 3rd quarter. Two Seas Capital LP now owns 4,612,692 shares of the company’s stock valued at $155,817,000 after buying an additional 1,464,187 shares in the last quarter. Engineers Gate Manager LP raised its stake in shares of Immunovant by 179.7% during the 2nd quarter. Engineers Gate Manager LP now owns 24,220 shares of the company’s stock worth $933,000 after acquiring an additional 15,560 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of Immunovant during the 2nd quarter worth approximately $2,996,000. Nykredit A S purchased a new stake in Immunovant during the second quarter valued at approximately $174,000. Finally, Corient Private Wealth LP lifted its position in Immunovant by 1.8% during the second quarter. Corient Private Wealth LP now owns 24,522 shares of the company’s stock valued at $945,000 after acquiring an additional 442 shares during the last quarter. Hedge funds and other institutional investors own 47.08% of the company’s stock.

Immunovant Company Profile

(Get Free Report)

Immunovant, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases. The company’s approach centers on targeting the neonatal Fc receptor (FcRn), a protein involved in the recycling of immunoglobulin G antibodies that can contribute to autoimmune activity.

Immunovant’s lead product candidate is batoclimab (IMVT-1401), a fully human monoclonal antibody designed to reduce circulating disease-causing antibodies. The company has evaluated batoclimab in several autoimmune conditions, including generalized myasthenia gravis and Graves’ disease, and has also pursued development in other antibody-mediated disorders.